120 likes | 240 Views
Providing Prescription Drug Coverage to the Elderly: America’s Experiment with Medicare Part D By Mark Duggan, Patrick Healy, and Fiona Scott Morton. Taylor Melanson. History of Medicare Part D. Medicare did not cover drugs (1966-2006) % of healthcare costs accounted for by drugs
E N D
Providing Prescription Drug Coverage to the Elderly: America’s Experiment with Medicare Part DBy Mark Duggan, Patrick Healy, and Fiona Scott Morton Taylor Melanson
History of Medicare Part D • Medicare did not cover drugs (1966-2006) • % of healthcare costs accounted for by drugs • 4.5% – 1982 • 5.6% – 1994 • 10.1 – 2005 • Prior to Part D, 30% of 44 million beneficiaries lacked coverage for drugs (Neuman et al., 2007) • Medicare Prescription Drug, Improvement, and Modernization Act of 2003 • Took effect in 2006 -> Established Part D • 2007 – covered 24 million people, cost $39 billion
Why Study Part D? • Impact on health and economic well-being • Increase in government spending • “Attempt to use market mechanisms in the delivery of a large-scale entitlement program” (70) • Competition • Price negotiation • Preference matching
Coverage Plans • Stand-alone plans • Basic plans • Government defined standard • “actuarially equivalent” • Many options • 4% of plans cover more than half of enrollees
Standard Cost Sharing Scheme Monthly premium Deductible = $275 Low cost coverage Donut hole Catastrophic coverage Only 17% of plans
Coverage of Medications • Basic Plan coverage - $1676 + catastrophic coverage • Formularies • Tier system • Prior authorization • Step therapy • Off formulary drugs
Choice of Plan • Out-of-pocket cost • Formulary status of current drugs • Maintenance vs acute need drugs • Reputation • Incentive to enroll early • Incentivizes alternative plans • 2008 - 10% of eligible people did not enroll
Influence on Drug Prices • Formulary placement • Incentives for patients and pharmacies • Average price of drugs declined • Treatments without substitutes • CMS required coverage • Protected Classes
Incentives for Sponsors • Firms make bid to CMS • Base beneficiary premium • Incentives to make bid accurate • Risk factor adjustment • Offsets approximately ¼ of variance in drug spending • Plans have better data than government • Catastrophic coverage • Risk absorption
Issues Enrollees without financial incentives Catastrophic coverage Formulary manipulation Inefficient treatment patterns Impact on budget
Conclusions • Successes • Drug prices • Drug utilization • Costs • Failures • Suboptimal choices • Treatments without substitutes • Administrative costs • Unsuccessful incentives
Citations • Images • http://www.epsilonregistration.com/ERImages/378/CMS%20log%20blue.jpg • http://www.alan.com/wp-content/uploads/2012/04/doughnut_21023028-300x286.jpg • http://www.mymedicarematters.org/images/copayGraphic.gif